Pubblicazioni

Autori:

Foà, Robin; Bassan, Renato; Elia, Loredana; Piciocchi, Alfonso; Soddu, Stefano; Messina, Monica; Ferrara, Felicetto; Lunghi, Monia; Mulè, Antonino; Bonifacio, Massimiliano; Fracchiolla, Nicola; Salutari, Prassede; Fazi, Paola; Guarini, Anna; Rambaldi, Alessandro; Chiaretti, Sabina

Titolo:

Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL

Anno:

2024

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

Journal of Clinical Oncology

ISSN Rivista:

0732-183X

N° Volume:

42

Numero o Fascicolo:

8

Intervallo pagine:

881-885

Parole chiave:

acute lymphoblastic leukaemia; philadelphia chromosome

Breve descrizione dei contenuti:

: Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We report the long-term results of the frontline trial with dasatinib and blinatumomab in induction/consolidation (GIMEMA LAL2116, D-ALBA) for adult Philadelphia-positive ALL (Ph+ ALL), which enrolled 63 patients of all ages. At a median follow-up of 53 months, disease-free survival, overall survival, and event-free survival are 75.8%, 80.7%, and 74.6%, respectively. No events have occurred among early molecular responders. A significantly worse outcome was recorded for IKZF1plus patients. Twenty-nine patients-93.1% being in molecular response (ie, complete molecular response or positive nonquantifiable) after dasatinib/blinatumomab-never received chemotherapy/transplant and continued with a tyrosine kinase inhibitor only; 28 patients remain in long-term complete hematologic response (CHR). An allogeneic transplant was carried out in first CHR mainly in patients with persistent minimal residual disease; 83.3% of patients are in continuous CHR. The transplant-related mortality was 12.5% for patients transplanted in first CHR and 13.7% overall. Nine relapses and six deaths have occurred. ABL1 mutations were found in seven cases. The final analysis of the D-ALBA study shows that a chemotherapy-free induction/consolidation regimen on the basis of a targeted strategy (dasatinib) and immunotherapy (blinatumomab) is effective in inducing durable long-term hematologic and molecular responses in adult Ph+ ALL, paving the way for a new era in the management of these patients.

Id prodotto:

139899

Handle IRIS:

11562/1127397

ultima modifica:

21 novembre 2024

Citazione bibliografica:

Foà, Robin; Bassan, Renato; Elia, Loredana; Piciocchi, Alfonso; Soddu, Stefano; Messina, Monica; Ferrara, Felicetto; Lunghi, Monia; Mulè, Antonino; Bonifacio, Massimiliano; Fracchiolla, Nicola; Salutari, Prassede; Fazi, Paola; Guarini, Anna; Rambaldi, Alessandro; Chiaretti, Sabina, Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL «Journal of Clinical Oncology» , vol. 42 , n. 8 , 2024 , pp. 881-885

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo